Analytical Data
-
Gene name
HLA-DRA1*01:01&HLA-DRB1*04:01&Influenza HA(PKYVKQNTLKLAT) Monomer
- Application
-
Alternative Names
HLA-DRA1*0101 & HLA-DRB1*0401 & Influenza HA (PKYVKQNTLKLAT)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
CAI2388006.1 (I26-E216)&CAI9239961.1
-
Expression Region
CAI2388006.1 (I26-E216)&CAI9239961.1 (G30-K227)&PKYVKQNTLKLAT
-
Molecular Weight
33-40 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-DRA1*01:01 and HLA-DRB1*04:01 in relation to the Influenza Hemagglutinin (HA) peptide PKYVKQNTLKLAT focuses on understanding the immune response to influenza infection and the role of specific human leukocyte antigen (HLA) alleles in presenting viral antigens. HLA molecules are critical for the immune recognition of pathogens, as they present peptide fragments to T cells, initiating an adaptive immune response. The selected HLA class II alleles, DRA1*01:01 and DRB1*04:01, are known for their association with various autoimmune diseases and their differential ability to present specific peptide sequences. The PKYVKQNTLKLAT peptide represents a critical epitope derived from the HA protein of influenza viruses, which plays a key role in viral entry into host cells. By analyzing the binding and presentation of this peptide by the HLA-DRA1*01:01 and HLA-DRB1*04:01 monomer recombinant proteins, researchers aim to elucidate the mechanisms of T cell activation and the subsequent immune response to influenza infections. This research could unlock insights into how genetic variability in HLA alleles influences susceptibility to the flu, vaccine efficacy, and the broader implications for vaccine design and personalized medicine strategies against influenza and other viral pathogens.
